CORT
Corcept Therapeutics Incorporated
114.90$
+2.7%
vs. previous close
Closing price · As of: Sep 17, 2026
Ownership
Ownership Structure
Who owns Corcept Therapeutics Incorporated (CORT)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 89.3% of the shares are freely tradable; institutional investors hold 75.7%.
Institutional ownership
?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
75.7%
Insiders
?Share of the stock held by the executives, founders and major shareholders of the company itself.
11.5%
Float
?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
89.3%
Short % of float
?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
11.2%
Shares Outstanding
?Total number of shares issued. Price times share count gives market cap.
108Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 11.24 | 12,151,276 | +0.7 | 03/31/2026 |
| Ingalls & Snyder LLC | 7.04 | 7,608,716 | +5.7 | 03/31/2026 |
| Renaissance Technologies Corp | 5.26 | 5,682,783 | -1.3 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 4.46 | 4,820,568 | +0.0 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.77 | 4,077,196 | +0.0 | 03/31/2026 |
| Parallel Advisors, LLC | 3.68 | 3,977,404 | +2.5 | 03/31/2026 |
| State Street Corp | 2.96 | 3,200,946 | +7.2 | 03/31/2026 |
| FMR Inc | 2.95 | 3,190,192 | +32.1 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 5.39 | 5,821,534 | +0.0 | 08/31/2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 2.69 | 2,903,493 | +0.3 | 07/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Mahoney David L | Director | 1,133,539 | 130,243,631 $ | Aug 18, 2026 | indirect |
| Wilson James N | Director | 1,064,543 | 122,315,991 $ | Sep 15, 2026 | indirect |
| Robb Gary Charles | Chief Business Officer | 68,950 | 7,922,355 $ | Aug 12, 2026 | both |
| Mokari Atabak | Chief Financial Officer | 16,304 | 1,873,330 $ | Sep 2, 2026 | direct |
| Maduck Sean | See Remarks | 9,938 | 1,141,876 $ | Sep 2, 2026 | direct |
| Lyon Joseph Douglas | See Remarks | 5,683 | 652,977 $ | Sep 14, 2026 | direct |
| Guyer William | Chief Development Officer | 4,313 | 495,564 $ | Sep 1, 2026 | direct |
| Vieira Roberto Wandenkolk | President, Oncology | 4,242 | 487,406 $ | Sep 2, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | Wilson James N | Director | Sell | 2,800 | 111.70 | 312,771 |
| Sep 15, 2026 | Wilson James N | Director | Sell | 400 | 110.84 | 44,335 |
| Sep 15, 2026 | Wilson James N | Director | Sell | 6,800 | 110.27 | 749,835 |
| Sep 14, 2026 | Lyon Joseph Douglas | See Remarks | Sell | 2,188 | 114.12 | 249,686 |
| Sep 14, 2026 | Lyon Joseph Douglas | See Remarks | Sell | 7,812 | 113.32 | 885,261 |
| Sep 14, 2026 | Lyon Joseph Douglas | See Remarks | Other | 7,404 | 13.56 | 100,398 |
| Sep 14, 2026 | Lyon Joseph Douglas | See Remarks | Other | 2,596 | 11.35 | 29,465 |
| Sep 2, 2026 | Maduck Sean | See Remarks | Other | 117 | 113.38 | 13,265 |
| Sep 2, 2026 | Mokari Atabak | Chief Financial Officer | Other | 102 | 113.38 | 11,565 |
| Sep 2, 2026 | Robb Gary Charles | Chief Business Officer | Other | 91 | 113.38 | 10,318 |
| Sep 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | Sell | 1,225 | 115.44 | 141,413 |
| Sep 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | Sell | 5,621 | 114.58 | 644,042 |
| Sep 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | Sell | 1,606 | 113.72 | 182,632 |
| Sep 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | Sell | 974 | 112.40 | 109,474 |
| Sep 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | Sell | 1,537 | 111.37 | 171,181 |
| Sep 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | Sell | 23,770 | 110.70 | 2,631,349 |
| Sep 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | Sell | 23,600 | 109.35 | 2,580,674 |
| Sep 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | Other | 58,333 | 21.63 | 1,261,743 |
| Sep 2, 2026 | Vieira Roberto Wandenkolk | President, Oncology | Other | 102 | 113.38 | 11,565 |
| Sep 2, 2026 | Lyon Joseph Douglas | See Remarks | Other | 72 | 113.38 | 8,163 |
| Sep 1, 2026 | Guyer William | Chief Development Officer | Other | 164 | 0.00 | – |
| Sep 1, 2026 | Maduck Sean | See Remarks | Other | 150 | 0.00 | – |
| Sep 1, 2026 | Maduck Sean | See Remarks | Sell | 2,281 | 115.61 | 263,711 |
| Sep 1, 2026 | Maduck Sean | See Remarks | Sell | 10,989 | 114.71 | 1,260,568 |
| Sep 1, 2026 | Maduck Sean | See Remarks | Sell | 11,730 | 113.94 | 1,336,459 |
| Sep 1, 2026 | Maduck Sean | See Remarks | Other | 25,000 | 8.27 | 206,750 |
| Sep 1, 2026 | Mokari Atabak | Chief Financial Officer | Other | 138 | 0.00 | – |
| Sep 1, 2026 | Robb Gary Charles | Chief Business Officer | Other | 164 | 0.00 | – |
| Sep 1, 2026 | Vieira Roberto Wandenkolk | President, Oncology | Other | 138 | 0.00 | – |
| Sep 1, 2026 | Lyon Joseph Douglas | See Remarks | Other | 130 | 0.00 | – |
| Aug 26, 2026 | Park Kimberly | Director | Sell | 26,685 | 122.55 | 3,270,169 |
| Aug 26, 2026 | Park Kimberly | Director | Other | 3,315 | 122.09 | 404,728 |
| Aug 26, 2026 | Park Kimberly | Director | Other | 30,000 | 13.49 | 404,700 |
| Aug 25, 2026 | Maduck Sean | See Remarks | Sell | 5,870 | 126.06 | 739,965 |
| Aug 25, 2026 | Maduck Sean | See Remarks | Sell | 25,085 | 125.47 | 3,147,355 |
| Aug 25, 2026 | Maduck Sean | See Remarks | Other | 30,955 | 11.35 | 351,339 |
| Aug 18, 2026 | Mahoney David L | Director | Sell | 400 | 119.64 | 47,855 |
| Aug 18, 2026 | Mahoney David L | Director | Sell | 7,055 | 118.88 | 838,710 |
| Aug 18, 2026 | Mahoney David L | Director | Sell | 91,167 | 118.24 | 10,779,367 |
| Aug 18, 2026 | Mahoney David L | Director | Sell | 4,984 | 117.47 | 585,478 |
| Aug 17, 2026 | Robb Gary Charles | Chief Business Officer | Sell | 10,000 | 116.26 | 1,162,572 |
| Aug 17, 2026 | Robb Gary Charles | Chief Business Officer | Other | 125 | 0.00 | – |
| Aug 14, 2026 | Maduck Sean | See Remarks | Sell | 3,664 | 114.49 | 419,491 |
| Aug 14, 2026 | Maduck Sean | See Remarks | Other | 3,664 | 8.27 | 30,301 |
| Aug 14, 2026 | Wilson James N | Director | Sell | 2,279 | 112.64 | 256,706 |
| Aug 14, 2026 | Wilson James N | Director | Sell | 4,668 | 111.44 | 520,214 |
| Aug 14, 2026 | Wilson James N | Director | Sell | 3,053 | 110.49 | 337,341 |
| Aug 12, 2026 | Robb Gary Charles | Chief Business Officer | Other | 3,000 | 0.00 | – |
| Aug 12, 2026 | Robb Gary Charles | Chief Business Officer | Other | 11,530 | 0.00 | – |
| Aug 10, 2026 | Maduck Sean | See Remarks | Sell | 1,031 | 114.52 | 118,068 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.